Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Quarterly numbers beat forecasts at Goldman Sachs

(Sharecast News) - Quarterly profits at Goldman Sachs comfortably beat expectations on Thursday, boosted by higher investment banking fees and bumper trading revenues. Diluted earnings per share rose to $14.01 in the three months to December end at the Wall Street bank, up from $11.95 a year previously. Consensus had been for EPS of $11.67.

Net earnings were 12% higher at $4.6bn, also ahead of consensus, for $3.9bn.

Driving the improvement was a 25% surge in investment banking fees, to $2.58bn, and a 25% spike in equities trading revenues, to a record $4.31bn.

Fixed income, currencies and commodities revenues were also stronger, rising 12% to $3.11bn.

Overall, fourth-quarter net revenues fell 3% to $13.45bn. The figure was dragged down by a sharp slide in platform solutions revenues, following markdowns on the outstanding credit card portfolio relating to the transfer of Apple credit card loans.

Goldman Sachs agreed to transfer the portfolio to JPMorgan Chase earlier this month, as part of wider plans to move away from the consumer market.

Even with weakness in platform solutions, however, over the full-year net revenues jumped 9% at $58.28bn, while diluted EPS soared to $51.32 from $40.54.

As at 1430 GMT, shares in Goldman Sachs had put on 2% as trading got underway in New York.

Share this article

Related Sharecast Articles

Culture Secretary 'minded to intervene' in Sky-ITV deal
(Sharecast News) - Culture secretary Lisa Nandy on Thursday revealed that she is "minded to intervene" in Sky's proposed takeover of ITV's media and entertainment activities, suggesting possible legislation of the streaming industry may be needed.
AstraZeneca enters into strategic drug discovery deal with AI biotech Insitro
(Sharecast News) - AstraZeneca said on Thursday that it will pay up to $1.86bn to enter a new strategic drug discovery collaboration and licensing agreement with Califiornia-based AI biotech firm Insitro.
Berenberg lifts target price on Discoverie following H1 update
(Sharecast News) - Analysts at Berenberg lifted their target price for DiscoverIE from 1,050p to 1,100p on Thursday, citing sustained organic momentum, a strengthening order book and earnings running ahead of expectations.
Friday preview: Man Group update, eurozone inflation eyed
(Sharecast News) - Friday will mark a fairly quiet end to a busy week that saw the release of a slew of US bank earnings.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.